Posted: November 8, 2009

NanoTecNexus and NanoTumor Center launch first-of-its-kind webinar series

(Nanowerk News) NanoTecNexus (NTN), formerly NanoBioNexus, already acclaimed for its educational forums and nanobiotechnology expertise, announces the launch of new courses, seminars, and lectures to be delivered online with proven and easy to use webinar tools. The webinar series initiative is part of NTN’s strategy to reach broad geographically dispersed communities, leverage scientific and business experts worldwide, and deliver the highest caliber content in a cost-effective manner.
Kicking off the initiative is a first of its kind Continuing Medical Education (CME) accredited webinar series entitled “Nanomedicine: New Strategies and Innovations to Understand, Treat, and Monitor Disease” sponsored by the UC San Diego School of Medicine and produced in partnership with the UC San Diego NanoTumor Center (NTC). The first of six sessions is scheduled for Friday November 20, at 11 am Pacific. Brochure and details follow.
The NanoTumor Center, a public-private consortium funded by the National Cancer Institute Alliance for Nanotechnology and led by UC San Diego, is dedicated to the translational application of nanotechnology in the fight against cancer. NanoTecNexus, a member of this consortium and lead for the NTC educational projects, led the planning committee in the design and organization of the webinar series to meet the accreditation standards and requirements.
“Education in the new field of cancer nanotechnology for the scientific and clinical communities as well as the general public is an integral part of our center,” said NTC Director Sadik Esener, PhD, Professor of Electrical and Computer Engineering at the UCSD Jacobs School of Engineering.
“The public needs to be aware of and informed about progress in cancer research in key fields such as nanotechnology,” noted Dennis Carson, MD, Director of the Moores UCSD Cancer Center, an NTC member. “These types of educational projects are vital to its continued support and success.”
The nanomedicine webinar series, the first of many to come, is designed for the clinical and research communities worldwide as well as industry professionals and general public interested in learning about progress made in medical research. The goal is to educate on the translational progress of applications using nanotechnology to address disease. “We are committed to fill an important void and place the attention on real progress, not just promise or hype,” said Adriana Vela, Founder and CEO of NanoTecNexus. “I am proud to say that, since our inception, we have not wavered from delivering quality content.”
Additionally, industry and commercialization focused webinars are planned for delivery in January 2010. Experts in topics ranging from nanotech venture financing and the art of the term sheet to winning strategies for SBIR grant proposals are among commercialization topics being planned. The industry focused segments are designed for entrepreneurial and commercial companies as well as technology and business professionals interested in nanotechnology opportunities.
About NanoTecNexus
NanoTecNexus (NTN), formerly known as NanoBioNexus, is a leading non-profit organization headquartered in San Diego with offices in Tucson AZ, San Jose, CA and Vancouver, WA. NTN is dedicated to catalyzing collaboration and knowledge exchange in the nanotech field by connecting people, technology, industry and investment. NanoTecNexus enables constituents worldwide to keep up-to-date on the developments of cutting-edge nanotechnologies. Nanotechnology involves manipulating matter on an atomic or molecular scale smaller than 100 nanometers (1 nm=1 billionths of a meter) and taking advantage of properties that are present at that scale. Nanotechnology is used in thousands of applications in medicine and health, energy and water, defense and many others.
About Moores UCSD Cancer Center
The Moores UCSD Cancer Center is one of the nation’s 41 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer. For more information, visit
About the NanoTumor Center
The NTC is a five-year, $20-million National Cancer Institute (NCI)-funded public-private consortium and one of only eight such NCI-backed programs in the nation. UCSD physicians, engineers, chemists and biologists collaborate with colleagues at the Burnham Institute for Medical Research, in addition to various industry partners, to examine the potential uses of nanotechnology in cancer detection, imaging and treatment. For more information, visit
Source: NanoTecNexus